Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

184 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Mechanism-based models for topotecan-induced neutropenia.
Léger F, Loos WJ, Bugat R, Mathijssen RH, Goffinet M, Verweij J, Sparreboom A, Chatelut E. Léger F, et al. Among authors: bugat r. Clin Pharmacol Ther. 2004 Dec;76(6):567-78. doi: 10.1016/j.clpt.2004.08.008. Clin Pharmacol Ther. 2004. PMID: 15592328
Population pharmacokinetics of oxaliplatin.
Delord JP, Umlil A, Guimbaud R, Grégoire N, Lafont T, Canal P, Bugat R, Chatelut E. Delord JP, et al. Among authors: bugat r. Cancer Chemother Pharmacol. 2003 Feb;51(2):127-31. doi: 10.1007/s00280-002-0550-3. Epub 2002 Dec 4. Cancer Chemother Pharmacol. 2003. PMID: 12647013
Individual adaptive dosing of topotecan in ovarian cancer.
Montazeri A, Culine S, Laguerre B, Pinguet F, Lokiec F, Albin N, Goupil A, Déporte-Féty R, Bugat R, Canal P, Chatelut E. Montazeri A, et al. Among authors: bugat r. Clin Cancer Res. 2002 Feb;8(2):394-9. Clin Cancer Res. 2002. PMID: 11839654 Clinical Trial.
184 results